Top

Cellular Oncology

Published in:

01-12-2015 | Original Paper

Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report

Authors: Yanjie You, Haijun Li, Xin Qin, Yinpo Zhang, Wengang Song, Yonggang Ran, Fenglan Gao

Published in: Cellular Oncology | Issue 6/2015

Abstract

Background

Cyclin-dependent kinase 10 (CDK10) has recently been identified as a tumor suppressor and, concordantly, its encoding gene has frequently been found to be inactivated in various human cancers. Here, we examined the expression status of CDK10 in a panel of primary human breast cancers and evaluated its correlation with clinicopathological parameters and clinical outcome.

Methods

Western blotting was used to assess CDK10 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, immunohistochemistry was performed in 128 formalin-fixed, paraffin-embedded tumor tissues. Associations of CDK10 expression with various clinicopathological parameters were evaluated and Kaplan-Meier survival analyses and Cox proportional hazards models were used to estimate its effect on patient survival.

Results

We found that CDK10 protein expression was markedly decreased in cancer tissues compared to adjacent noncancerous tissues. Immunohistochemistry revealed decreased CDK10 levels in 65/128 (50.8 %) of the primary breast cancer tissues tested. These decreased levels were found to be significantly associated with lymph node metastasis (P = 0.003), advanced tumor stage (P < 0.001) and unfavorable overall survival (P < 0.001). Furthermore, multivariate analyses indicated that CDK10 expression may serve as an independent prognostic factor for survival (P = 0.001).

Conclusion

Down-regulated CDK10 expression frequently occurs in breast cancers and correlates with disease progression and poor survival. CDK10 may serve as a prognostic biomarker for breast cancer.

L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015)CrossRefPubMed

C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747–752 (2000)CrossRefPubMed

S. Di Cosimo, J. Baselga, Management of breast cancer with targeted agents: importance of heterogeneity. Nat. Rev. Clin. Oncol. 7, 139–147 (2010)CrossRefPubMed

J. Peppercorn, C.M. Perou, L.A. Carey, Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig. 26, 1–10 (2008)CrossRef

S. Tabarestani, S.M. Ghaderian, H. Rezvani, R. Mirfakhraie, A. Ebrahimi, H. Attarian, J. Rafat, M. Ghadyani, H.A. Alavi, N. Kamalian, A. Rakhsha, E. Azargashb, Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. Cell. Oncol. 37, 107–118 (2014)

A.H. Verschuur-Maes, C.B. Moelans, P.C. de Bruin, P.J. van Diest, Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnarcell lesions of the breast. Cell. Oncol. 37(147–154) (2014)

E. Yiannakopoulou, Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. Cell. Oncol. 37(1–8) (2014)

L.J. van’t Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, S.H. Friend, Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002)CrossRef

Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012)CrossRef

10.

E.A. Musgrove, R.L. Sutherland, Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643 (2009)CrossRefPubMed

11.

C.A. Hudis, Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007)CrossRefPubMed

12.

F. Bullrich, T.K. MacLachlan, N. Sang, T. Druck, M.L. Veronese, S.L. Allen, N. Chiorazzi, A. Koff, K. Heubner, C.M. Croce et al., Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res. 55, 1199–1205 (1995)PubMed

13.

J. Crawford, L. Ianzano, M. Savino, S. Whitmore, A.M. Cleton-Jansen, C. Settasatian, M. D’apolito, R. Seshadri, J.C. Pronk, A.D. Auerbach, P.C. Verlander, C.G. Mathew, A.J. Tipping, N.A. Doggett, L. Zelante, D.F. Callen, A. Savoia, The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. Genomics 56, 90–97 (1999)CrossRefPubMed

14.

E. Iorns, N.C. Turner, R. Elliott, N. Syed, O. Garrone, M. Gasco, A.N. Tutt, T. Crook, C.J. Lord, A. Ashworth, Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91–104 (2008)CrossRefPubMed

15.

C.J. Lord, E. Iorns, A. Ashworth, Dissecting resistance to endocrine therapy in breast cancer. Cell Cycle 7, 1895–1898 (2008)CrossRefPubMed

16.

P. Khanal, H.J. Yun, S.C. Lim, S.G. Ahn, H.E. Yoon, K.W. Kang, R. Hong, H.S. Choi, Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. Oncogene 31, 3845–3856 (2012)CrossRefPubMed

17.

C.W. Yeh, S.H. Kao, Y.C. Cheng, L.S. Hsu, Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression. J. Biol. Chem. 288, 27927–27939 (2013)PubMedCentralCrossRefPubMed

18.

J.H. Yu, X.Y. Zhong, W.G. Zhang, Z.D. Wang, Q. Dong, S. Tai, H. Li, Y.F. Cui, CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol. Rep. 27, 1266–1276 (2012)PubMedCentralPubMed

19.

X.Y. Zhong, X.X. Xu, J.H. Yu, G.X. Jiang, Y. Yu, S. Tai, Z.D. Wang, Y.F. Cui, Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene 498, 68–74 (2012)CrossRefPubMed

20.

Y. You, W. Yang, Z. Wang, H. Zhu, H. Li, C. Lin, Y. Ran, Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell. Oncol. 36, 323–331 (2013)CrossRef

21.

C.Q. Hong, F. Zhang, Y.J. You, W.L. Qiu, A.E. Giuliano, X.J. Cui, G.J. Zhang, Y.K. Cui, Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer 15, 548 (2015)PubMedCentralCrossRefPubMed

22.

Y. You, W. Yang, X. Qin, F. Wang, H. Li, C. Lin, W. Li, C. Gu, Y. Zhang, Y. Ran, ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell. Oncol. 38, 205–14 (2015)CrossRef

23.

A.S. Howell, D.J. Lew, Morphogenesis and the cell cycle. Genetics 190(1), 51–77 (2012)PubMedCentralCrossRefPubMed

24.

S. Mahale, S.B. Bharate, S. Manda, P. Joshi, P.R. Jenkins, R.A. Vishwakarma, B. Chaudhuri, Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization. Cell Death Dis. 6, e1743 (2015)CrossRefPubMed

25.

T. VanArsdale, C. Boshoff, K.T. Arndt, R.T. Abraham, Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin. Cancer Res. 21, 2905–2910 (2015)CrossRefPubMed

26.

Z. Feng, S. Xu, M. Liu, Y.X. Zeng, T. Kang, Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 297, 190–197 (2010)CrossRefPubMed

27.

V.J. Guen, C. Gamble, M. Flajolet, S. Unger, A. Thollet, Y. Ferandin, A. Superti-Furga, P.A. Cohen, L. Meijer, P. Colas, CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc. Natl. Acad. Sci. U. S. A. 110, 19525–19530 (2013)PubMedCentralCrossRefPubMed

28.

G. Heller, B. Ziegler, A. Brandstetter, S. Novak, M. Rudas, G. Hennig, M. Gehrmann, T. Acht, S. Zöchbauer-Müller, M. Filipits, CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res. 29, 3939–3944 (2009)PubMed

29.

A. Dhasarathy, M. Kajita, P.A. Wade, The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol. Endocrinol. 21, 2907–2918 (2007)PubMedCentralCrossRefPubMed

30.

Y. Ran, S. Wu, Y. You, Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 149, 49–54 (2011)

Title: Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report
Authors: Yanjie You
Haijun Li
Xin Qin
Yinpo Zhang
Wengang Song
Yonggang Ran
Fenglan Gao
Publication date: 01-12-2015
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 6/2015
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-015-0246-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2015

A simple method to overcome the inhibitory effect of heparin on DNA amplification

Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells

Inhibition of Ras-mediated signaling pathways in CML stem cells

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers

The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers

Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer